Anthropic announced the discovery of a novel enzyme system in bacterial DNA, which its flagship AI model Claude autonomously identified. The system exhibits characteristics of programmable genomic structures and displays a pattern reminiscent of CRISPR, the groundbreaking genome-editing mechanism.
According to the company, the discovery emerged from researchers at Anthropic’s newly established biology lab in San Francisco, who prompted Claude to analyze a large database of DNA sequences. The AI required approximately 21 hours of searching before locating the system.
Anthropic noted that the function of the newly identified system remains undetermined, though the company suspects it could represent a new gene-editing mechanism. In a post on X, CEO Dario Amodei emphasized that AI is still in the very early stages of making discoveries with the potential to lead to medical breakthroughs, including the possibility of curing diseases within five to ten years.
Amodei expressed support for frontier labs exploring biological discovery, stating his genuine enthusiasm for the potential outcomes of such research.
Stanley Qi, associate professor of bioengineering at Stanford University, described the reported discovery as incredibly exciting. He highlighted the AI’s ability to recognize and comprehensively pursue an unusual biological pattern that has historically been difficult to detect, suggesting that AI could greatly expand our capacity to explore nature’s molecular diversity more effectively and rapidly.
However, the announcement has met with skepticism. Kevin Blake, a microbiologist at Washington University School of Medicine, cautioned that labeling the find as “CRISPR-like” does not necessarily equate to the next generation of CRISPR technology. Blake noted that countless CRISPR-like sequences remain unidentified due to the vast number of bacterial species yet to be studied, and there is no indication the system could be developed into therapeutic or practical applications.
The discovery comes amid context regarding the original CRISPR system, which Emmanuelle Charpentier and Jennifer Doudna pioneered for editing DNA in living organisms, earning them the 2020 Nobel Prize in Chemistry. Last year, the Children’s Hospital of Philadelphia achieved a historic medical breakthrough by using a customized CRISPR gene-editing therapy to successfully treat an infant born with carbamoyl phosphate synthetase 1 deficiency, a rare metabolic disease.
.png?w=1024&resize=1024,1024&ssl=1 "BAFL to list Rs20bn subordinated privately placed TFCs on PSX – Mettis Global")
